Biogen Inc.
(NASDAQ:BIIB)
$239.29
0.17 (0.07%)
At Close: 4:00 PM
Biogen Stock Price Graph
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- YTD
- All
Biogen Stock Price Today
Biogen Inc. (BIIB) stock rallied over 0.07% intraday to trade at $239.29 a share on NASDAQ. The stock opened with a gain of 0.37% at $240.00 and touched an intraday high of $240.01, rising 0.07% against the last close of $239.12. The Biogen Inc. in stock market went to a low of $233.76 during the session.
Biogen Stock Snapshot
$239.12
Prev. Close
34.67 Billion
Market Cap
$233.76
Day Low
$240.00
Open
N/A
Number of Shares
$240.01
Day High
23.79
P/E ratio
10.06
EPS (TTM)
15.79
Cash Flow per Share
N/A
Free Float in %
99.96
Book Value
929364.00
Volume
Biogen Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|
Contact Details
Company Information
EmployeesN/A
Beta0.03
Sales or Revenue$9.99 Billion
5Y Sales Change-2.56%
Fiscal Year EndsDec. 2022
SectorHealthcare
IndustryDrug Manufacturers—General
About Company
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Peers
Frequently Asked Questions
What is the current Biogen Inc. (BIIB) stock price?
Biogen Inc. (NASDAQ: BIIB) stock price is $239.29 in the last trading session. During the trading session, BIIB stock reached the peak price of $240.01 while $233.76 was the lowest point it dropped to. The percentage change in BIIB stock occurred in the recent session was 0.07% while the dollar amount for the price change in BIIB stock was $0.17.
BIIB's industry and sector of operation?
The NASDAQ listed BIIB is part of Drug Manufacturers—General industry that operates in the broader Healthcare sector. Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases.
Who are the executives of BIIB?
Dr. Mahalakshmi Radhakrishnan M.D.
Chief Medical Officer & Group Senior Vice President
Ms. Natacha Gassenbach
Chief Communication Officer & Head of Corporation Affairs
Dr. Ginger Gregory
Executive Vice President & Chief HR Officer
Mr. Christopher A. Viehbacher
Pres, Chief Executive Officer & Director
How BIIB did perform over past 52-week?
BIIB's closing price is 0.68% higher than its 52-week low of $233.76 where as its distance from 52-week high of $319.76 is -0.01%.
How many employees does BIIB have?
Number of BIIB employees currently stands at N/A. BIIB operates from 225 Binney Street, Cambridge, MA 02142, US.
Link for BIIB official website?
Official Website of BIIB is: https://www.biogen.com
How do I contact BIIB?
BIIB could be contacted at phone #617 679 2000 and can also be accessed through its website. BIIB operates from 225 Binney Street, Cambridge, MA 02142, US.
How many shares of BIIB are traded daily?
BIIB stock volume for the day was 929364.00 shares. The average number of BIIB shares traded daily for last 3 months was 978.18 Thousands.
What is the market cap of BIIB currently?
The market value of BIIB currently stands at $34.67 Billion with its latest stock price at $239.29 and N/A of its shares outstanding.